Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics develops briquilimab, a clinical-stage antibody therapy targeting KIT (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Company news centers on briquilimab clinical data from BEACON, open-label extension and ETESIAN studies, financial results and corporate updates, investor conference participation, financing activity and governance changes tied to its development strategy.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced its Q3 2021 results, marking a significant quarter post-IPO. The company raised $100 million in gross proceeds after merging with Amplitude Healthcare Acquisition Corporation. JSP191 clinical trials are on track, with top-line interim data expected in Q1 2022. The company secured FDA Orphan and Rare Pediatric Disease designations for JSP191. Cash reserves of $100.9 million are projected to fund operations through mid-2023. Despite an increase in R&D expenses to $7.2 million, the net loss narrowed to $3.4 million from $10.8 million in Q3 2020.
Jasper Therapeutics (JSPR) announces a non-exclusive research collaboration with AVROBIO to explore JSP191 as a targeted conditioning agent for patients with Fabry disease and Gaucher disease type 1 undergoing AVROBIO's gene therapies. CEO Bill Lis emphasized the collaboration enhances JSP191's potential in gene therapies. JSP191 is an anti-CD117 monoclonal antibody in clinical development, currently evaluated in over 90 healthy volunteers and patients, with ongoing trials for various hematological conditions.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) will be presenting at the Credit Suisse 30th Annual Virtual Healthcare Conference on November 10, 2021, at 11:40 a.m. Pacific Time. Bill Lis, Executive Chairman and CEO, will lead the presentation, which will be available via a live webcast. Jasper focuses on hematopoietic cell transplant therapies, with two promising programs in development: JSP191, a monoclonal antibody aimed at safer transplants, and a preclinical mRNA engineered hematopoietic stem cell platform. Their innovations aim to expand treatment options for patients with serious medical conditions.